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Background: The aim of the present study was to evaluate if the inﬂuence of digitalis on survival depends on
the severity of cardiac dysfunction in heart failure (HF).
Methods and results: Doppler echocardiogram (DE) parameters were analyzed in 84Wistar control (C) and 80
Wistar rats treated with 0.1 mg/100 g/day of digitoxin (D) ﬁve days after coronary occlusion. The DE vari-
ables correlated with the survival of the animals were: myocardial infarction size, left chamber dimensions,
fractional area change and E/A ratio. The animals were observed for up to 280 days. Mortality was worsened
in rats in the D group with a myocardial infarction (MI)b37% and with better DE predictors of survival. Digi-
toxin was found to prolong survival in rats with an MI≥37% and worse DE predictors.
Conclusion: For the ﬁrst time our study has shown experimentally that the action of digitalis glycosides can
positively or negatively inﬂuence survival during treatment of HF. It prolongs survival of those in advanced
state and compromises survival when there is less severity of the disease. In fact, the greater beneﬁts occur
when digitoxin was used in heightened ventricular dilatations and worse ventricular performance.© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
Clinical and experimental studies have demonstrated that angio-
tensin converting-enzyme inhibitors [1], beta-adrenergic antagonists
[2], and aldosterone antagonists [3] provide an unquestionable bene-
ﬁt in patients with heart failure (HF), leading not just to a clinical im-
provement but also to an increase in survival.
In the Digitalis Investigation Group (DIG) study [4], overall mor-
tality was not affected in patients treated with digoxin, even though
there were reductions in symptoms of HF and hospitalizations. Not-
withstanding, it was suggested that, in patients with severe cardiac
dysfunction and HF, digoxin may have beneﬁcial therapeutic actions.
Indeed, in the DIG study [4], the combined outcome of mortality from
worsening heart failure or hospitalization was lower in the digoxin
group than in placebo group and these beneﬁts were greater among
patients with lower ejection fractions or enlarged hearts and those
in NYHA functional class III or IV.
In a recent study, we demonstrated that digitalis prolongs the life
of rats with HF secondary to myocardial infarction (MI) [5]. Using
Doppler echocardiogram (DE), we previously identiﬁed certain pa-
rameters associated with shorter survival in female rats with HF due
to coronary occlusion [6]. These DE parameters have not yet been4, CEP: 04022-000-São Paulo-
).
nder the Elsevier OA license. used in experimental studies to evaluate the merits of a speciﬁc ther-
apy in improving survival.
The aim of this present study was to evaluate whether the inﬂu-
ence of digitalis on survival depends on the severity of cardiac dys-
function. We have analyzed DE parameters that were previously [6]
considered to have prognostic value for mortality in female rats
with a MI. The DE was obtained during the acute phase of an MI
and the data were correlated with the survival of the animals. Asses-
sing these parameters is particularly important for the therapeutic
use of digitalis since it will be possible to reinforce the theory that
digitalis may be effective in decreasing mortality in worst prognosis
cases of HF.
2. Methods
The data of the present study were obtained from the female rats evaluated in a
previous experiment, which analyzed the effect of digitoxin on the survival of rats
with HF secondary to a large MI [5]. The DE parameters of 164 Wistar-EPM rats, age
70 to 90 days when infarcted and weighing between 180 g and 220 g, were reevalu-
ated. The animals were provided by the animal facilities of the Federal University of
São Paulo. They were kept in plastic cages under a 12-hour light/dark cycle at room
temperature (22 °C to 23 °C). Animals were given free access to food and water and
were fed either standard regular rat chow (control animals) or a standard diet supple-
mented with 1% digitoxin (digitoxin group). This concentration of digitoxin was deter-
mined taking into account that: (i) orally administered digitoxin is completely
absorbed; (ii) a daily dose similar to the one used in the present study was shown pre-
viously to be as efﬁcient in promoting cardiac beneﬁts in the rat (100 g/kg per day)
when injected subcutaneously [5]; (iii) healthy young and adult rats in our laboratory
eat approximately 30 g food daily. Digitoxin (1 mg) was diluted in absolute ethyl alco-
hol (3 mL) and sprayed in and mixed with standard diet (100 g). The resultant chow,
with digitoxin added and mixed with water, resulted in a dough. Chow pellets were
Table 1
Doppler echocardiogram parameters for control (C) and digitoxin-treated (D) rats
according to myocardial infarction size.
Parameter C≥37% D≥37% Cb37% Db37%
n=57 n=56 n=27 n=24
LVDDb0.82 cm 31 (54%) 35 (63%) 22 (81%) 16 (67%)
LVDD≥0.82 cm 26 (46%) 21 (38%) 5 (19%) 8 (33%)
LVSDb0.62 cm 21 (37%) 31 (55%) 16 (59%) 18 (75%)
LVSD≥0.62 cm 36 (63%) 25 (45%) 11 (41%) 6 (25%)
LVDAb0.42 cm² 25 (44%) 25 (45%) 21 (78%) 18 (75%)
LVDA≥0.42 cm² 32 (56%) 30 (55%) 6 (22%) 6 (25%)
LVSAb0.26 cm² 16 (28%) 18 (33%) 20 (74%) 19 (79%)
LVSA≥0.26 cm² 41 (72%) 37 (67%) 7 (26%) 5 (21%)
FAC>37% 14 (25%) 9 (16%) 24 (89%) 15 (63%)*
FAC≤37% 43 (75%) 46 (82%) 3 (11%) 9 (38%)
E/Ab3.04 14 (25%) 12 (22%) 23 (85%) 18 (75%)
E/A≥3.04 43 (75%) 42 (75%) 4 (15%) 6 (25%)
FAC>37% e E/Ab3.04 19 (33%) 17 (30%) 20 (74%) 18 (75%)
FAC≤37% e E/A≥3.04 38 (66%) 36 (64%) 7 (26%) 6 (25%)
C: control; D: digitoxin; LVDD: left ventricular diastolic diameter; LVSD: left ventricular
systolic diameter; LVDA: left ventricular diastolic area; LVSA: left ventricular systolic
area; FAC: fraction area change; E: E wave; A: A wave. * Values are absolute and relative
frequencies. * pb0,05 for comparison of the qualitative parameters (Fischer exact test)
between C and D groups.
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alcohol.
The study was approved by the Ethics and Research Committee of the Federal
University of São Paulo. The animals were observed for no more than 280 days.
3. Infarction
The rats underwent occlusion of anterior descending coronary ar-
tery as previously described [5-11]. Five days after coronary occlu-
sion, the rats were anesthetized (ketamine 90 mg/kg and xylazine
10 mg/kg given intraperitoneally) and subjected to a DE in order to
characterize the presence and the size of the MI. Thereafter, the ani-
mals were randomized to either the control group (C), that received
standard rat chow containing 0.6% of sodium (Nuvilab CR1, Nuvital,
Curitiba, Brazil) or to the digitoxin group (D), that received standard
rat chow with added digitoxin, as previously described [5].
4. Doppler echocardiogram
Five days after the surgical procedure, DE was performed. A Sonos
5500 (Philips, Andover, Massachusetts) was used with a 5- to 12-
MHz transducer at a 2- to 3-cm depth. The animals were anesthetized
as for the surgical procedure, weighed (in grams), had their chest an-
terior wall shaved, and then placed in left lateral decubitus position.
Three electrodes were attached to the paws of the animals for simul-
taneous 1-lead electrocardiogram trace. Echocardiograms of both lon-
gitudinal and transversal parasternal, as well as 2- and 4-chamber
apical views of the LV were obtained. Velocity curves of mitral inﬂow
and LV outﬂow tracts by spectral Doppler were also obtained.
Myocardial infarct sizewasmeasured by 2-dimensional echocardio-
gram and based on LV basal, midtransversal, and apical transversal
views. Three measures of the endocardial perimeter (EP) of the LV cav-
ity and the length of the segment with infarction (ISe) for each trans-
verse view were obtained during diastole. The infarct size for each
segment (ISi), expressed as the proportion of the LV perimeter of each
transverse view, was calculated by the equation: ISi (%)=ISe/
EP×100. The total infarct size of each animal was calculated as the
mean of the ISi (%) of the 3 segments. Myocardial infarction assessed
by echocardiogram was deﬁned as any segment with increased echo-
genicity and/or change in myocardial thickening or systolic movement
(hypokinesia, akinesia, or dyskinesia). The accuracy of MI size by this
method was previously deﬁned [8]. Those animals presenting with an
MI of 20% ormore of the LV EPwere identiﬁed by an ID 100 implantable
Trovan transponder (Trovan Electronic Identiﬁcation System, Ulm,
Germany) afﬁxed to the nape of the neck. Those rats with an MI less
than 20% were not considered in this study. Left ventricular diastolic
(LVDD) and systolic (LVSD) diameters were measured by M mode or
2-dimensional images at the mid-LV chamber. Additionally, both dia-
stolic (LVDA) and systolic transverse areas (LVSA) of the LV were mea-
sured by 2-dimensional echocardiogram at basal, midview, and apical
views. The ﬁnal value was the arithmetic mean of the measures of the
3 views.
Systolic function was analyzed by the fractional area change
(FAC=LVDA−LVSA/LVDA); diastolic function was evaluated based
onmitral inﬂow determined by pulsed wave Doppler. From the mitral
diastolic ﬂow velocity curve, the maximum velocity of the E and A
waves were measured and the E/A ratio calculated.
After determination of the size of the MI, the C and D group rats
were divided into 4 subgroups: 1) Cb37%: control infarcted group
with an MI of less than 37% of the LV; 2) Db37%: digitoxin-treated
rats with an MI of less than 37% of the LV; 3) C≥37%: control infarct-
ed group with an MI of 37% or more of the LV; and 4) D≥37%:
digitoxin-treated rats with an MI of 37% or more of the LV. The cutoff
MI point for groups division (37%) was taken from our previous study
[6], which associated this value with greater risk of death (relative
risk [RR] 8.4, 95% conﬁdence interval [CI] 2.99–23.56).5. Parameters associated with mortality
According to the univariate analysis of our previous study [6] on
female rats with HF after left coronary occlusion, the DE parameters
associated with a shorter survival time were: MI size≥37% (RR 8.4,
95% CI 2.99–23.56); LVDA≥0.42 cm² (RR 4.34, 95% CI 2.31–8.16);
LVDD≥0.82 cm (RR 2.39; 95% CI 1.33–4.32); LVSA≥0.26 cm² (RR
7.98, 95% CI 3.68–17.32); LVSD≥0.62 cm (RR 3.43, 95% CI 1.79–
6.56); FAC≤37% (RR 10.27, 95% CI 4.30–24.52); E/A≥3.04 (RR 4.72,
95% CI 2.32–9.59). Parameters associated with higher mortality
based on Cox multivariate model [6] included LVSA≥0.26 cm² (RR
4.58, 95% CI 1.99–10.54) and FAC≤37% associated with an E/A
ratio≥3.04 (RR 2.99, 95% CI 1.44–6.18). In this study, parameters as-
sociated with the survival of the animals were assessed by Cox uni-
variate and multivariate regression models and divided into 4
groups according to infarction critical size, as previously mentioned:
Cb37%, Db37%, C≥37%, and D≥37%.
6. Statistical analysis
Qualitative variables were presented as relative and absolute fre-
quencies. The statistic test used to evaluate nominal data was the Fi-
scher exact test. The survival probability of infarcted female rats at
280 days was estimated using Kaplan-Meier method. The log-rank
test was used to compare survival as a function of each qualitative
variable of interest. The DE parameters evaluated in this study
were: MI size≥37% andb37%; LVDA≥0.42 cm² andb0.42 cm²;
LVDD≥0.82 cm andb0.82 cm; LVSA of LV≥0.26 cm² andb0.26 cm²;
LVSD≥0.62 cm andb0.62 cm; FAC≤37% associated with an E/
A≥3.04; and FAC>37% associated with an E/Ab3.04. P valuesb0.05
were considered signiﬁcant.
7. Results
Echocardiogram data of 164 female rats that underwent coronary
occlusion were analyzed. Eighty animals received digitoxin, and 84
untreated animals served as a control group. Fifty-six (70%) of the
digitoxin group and 57 (68%) of the control group had an MI≥37%.
There were 24 (30%) rats in the D group and 27 (32%) in the C
group with an MIb37%, respectively (p=0.07). Doppler echocardio-
gram parameters of rats in groups C and D with an MI≥37% were
similar. In the Cb37% group, rats had (p=0.049) an FAC>37%. No
Fig. 1. Kaplan–Meier curves comparing survival probability in female rats of Control and Digitoxin groups after myocardial infarction equal or larger than 37% (MI≥37%) and myo-
cardial infarction smaller than 37% (MIb37%).
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ters between groups Cb37% and Db37% (Table 1).
Rats in the D≥37% group showed a longer survival time compared
with the C≥37% group (p=0.03, Fig. 1). Interestingly, digitoxin re-
duced mortality in animals that showed DE parameters associated
with a poor prognosis (Fig. 2). There was a 35%, 43%, 35%, 37%, 27%,
29% and 29% reduction in mortality in the D≥37% group with respect
to LVDD≥0.82 cm, LVSD≥0.62 cm, LVDA≥0.42 cm2, LVSA≥0.26 cm²,
FAC≤37%, and E/A≥3.04 and FAC≤37%+E/A≥3.04 respectively
(Table 2). Rats with an MIb37% showed different results; digitoxin
did not improve survival in these animals (p=0.13). Moreover,
rats in the Db37% group had a higher mortality (Fig. 3) when
LVDDb0.82 cm and LVSDb0.62 cm (25% and 22% increases, respective-
ly; Table 3).
8. Discussion
In this present studywe observed a heterogeneous response to digi-
toxin among female rats with experimental HF secondary to coronaryFig. 2. Kaplan–Meier curves comparing survival probability after myocardial infarction in f
mates in the≥37% infarction digitoxin and placebo groups: A) FAC: fractional area change;
diameter; E) LVSA: left ventricle systolic area. *Pb0.05 (log rank test).occlusion. Rats with an infarction ≥37% and with echocardiogram pre-
dictors of mortality had prolonged survival times when treated with
digitoxin. There was an expressive prolonged survival time in rats
with an FAC≤37% and an E/A≥3.04. In contrast, rats with an infarction
b37% and with less LV dilatation and less cardiac function impairment
did not beneﬁt from digitoxin. Digitoxin treatment was harmful for
rats with an MIb37% and a LVDDb0.82 cm and an LVSDb0.62; these
animals had a 25% increase in mortality. These results help indicate
whether or not an animal will achieve a reduction in mortality with
the use of a cardiac glycoside. This treatment improved survival of rats
with worse remodeling and expressive impairment of cardiac mechan-
ical function and was harmful for animals with less ventricular dilata-
tion and better systolic performance.
Since the publication of the DIG study [4] – indicating that there was
no reduction in overall mortality following the use of digoxin – the use
of digitalis glycosides in the treatment of patients with HF decreased
dramatically. Additional analyses of the DIG data have allowed for new
interpretations of the results of the trial. Analysis of subgroups indicated
that digoxin reducedmortality in some patients. It was emphasized thatemale rats according to Doppler echocardiogram predictors of mortality. Survival esti-
B) E\A ratio; C) LVDD: left ventricle diastolic diameter; D) LVSD: left ventricle systolic
Table 2
Mortality rates for rats with myocardial infarction≥37% of left ventricle according to Doppler echocardiogram predictors of mortality.
Parameters D≥37% C≥37% Δ R-R (CI) p
n deaths n deaths
LVDD≥0.82 cm 21 8 (38%) 26 19 (73%) −35% 0.41 (0.19–0.87) 0.02
LVDDb0.82 cm 35 11 (31%) 31 14 (45%) −14% 0.59 (0.27–1.30)
LVSD≥0.62 cm 25 8 (32%) 36 27 (75%) −43% 0.31 (0.16–0.61) b0,001
LVSDb0.62 cm 31 11 (35%) 21 6 (29%) 6% 1.24 (0.47–3.28)
LVDA≥0.42 cm² 30 13 (43%) 32 25 (78%) −35% 0.39 (0.20–0.75) 0.004
LVDAb0.42 cm² 25 5 (20%) 25 8 (32%) −12% 0.55 (0.18–1.63)
LVSA≥0.26 cm² 37 15 (41%) 41 32 (78%) −37% 0.35 (0.19–0.62) b0.001
LVSAb0.26 cm² 18 3 (17%) 16 1 (6%) 11% 2.65 (0.37–18.81)
FAC≤37% 46 17 (37%) 45 29 (64%) −27% 0.44 (0.25–0.79) 0.006
FAC>37% 9 1 (11%) 12 4 (33%) 22% 0.34 (0.06–2.00)
E/A≥3.04 42 16 (38%) 43 29 (67%) −29% 0.41 (0.23–0.74) 0.003
E/Ab3.04 12 1 (8%) 14 4 (29%) −21% 0.33 (0.06–1.92)
FAC≤37%+E/A≥3.04 36 15 (42%) 38 27 (71%) −29% 0.41 (0.22–0.77) 0.005
FAC>37%+E/Ab3.04 20 4 (20%) 17 7 (41%) −21% 0.43 (0.13–1.42)
D: digitoxin; C: control; R-R Relative risk; CI: 95% conﬁdence interval; LVDD: left ventricular diastolic diameter; LVSD: left ventricular systolic diameter; LVDA: left ventricular di-
astolic area; LVSA: left ventricular systolic area; FAC: fraction area change; E: E wave; A: A wave. * Values are absolute and relative frequencies. pb0,05 for comparison of the qual-
itative parameters (chi-square test) between control and digitoxin groups with MI≥37%.
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an increase in mortality when digoxin serum levels were higher than
0.9 ng/mL. In patients with digoxin serum levels less than 0.9 ng/mL,
mortality was signiﬁcantly reduced when compared with that of
untreated patients. In addition, the DIG study reported that digoxin
was more beneﬁcial for high-risk patients [4]. Digoxin decreased hospi-
talization and mortality rates in patients with an ejection fraction less
than 25%, a high cardiothoracic index, and in functional classes III and
IV. Such analysis yields important information: that there are patient
groups that respond differently when digitalis glycosides are used to
treat HF. This present study is the ﬁrst known experimental demonstra-
tion of an increase in survival rates in advanced cardiopathy. Our data
support this assumption. Moreover, it strengthens the need for a new
clinical trial with digitalis glycosides in order to reevaluate the actual
role of these agents in certain clinical scenarios, as proposed by Ahmed
et al. [17].
The mechanisms by which digitalis glycosides prolong survival in
advanced cardiopathy and result in harm when given for cases with
small cardiac repercussion are yet to be established. In our previous
study [5] we conﬁrmed that, after a prolonged use of digitoxin
(280 days), the myocardial contractility capacity was enhanced com-
pared to untreated rats. We were not able to establish whether the
myocardial dysfunction attenuation was due to the inotropic effect
of digitoxin chronic use or to a lesser myocardial remodeling. In either
case, it is possible to assert that the beneﬁcial effects of digitalis glyco-
sides are more expressive when there is an intense myocardial insult,
whereas its inﬂuence on more benign cases is either irrelevant orFig. 3. Kaplan–Meier curves comparing survival probability after myocardial infarction in f
mates in theb37% infarction digitoxin and placebo groups: A) LVDD: left ventricle diastolicharmful. Also, an alternative to be considered is that the prolonged
survival of animals with HF may be a consequence of other pharma-
cological actions of the digitalis glycosides, which may contribute to
increased survival. Such actions include those that control hyperac-
tivity of the renin–angiotensin–aldosterone system and the sympa-
thetic nervous system [18]. There are indications that the
hyperactivity of these systems is proportional to the intensity of the
HF [19,20]. It is conceivable that animals with severe HF have a
more intense activity of these systems and might beneﬁt from the re-
duction caused by the digitalis glycosides. On the other hand, cardiop-
athy with smaller functional deﬁcits and less hyperactivity of the
adrenergic and the renin–angiotensin–aldosterone systems would
beneﬁt less.
Another question yet to be deﬁned is why digitalis glycosides re-
duce survival in animals with lesser cardiac impairment. The arrhyth-
mias caused by digitalis might be considered a limiting factor for
survival from cardiopathies treated with digitalis glycosides.
Thus, the ﬁnal effects of digitalis on survival would depend on the
balance between beneﬁcial effects, which occur when digitalis serum
levels are low in advanced cardiopathies, and the harmful effects that
occur with high serum levels of the drug in cardiopathies with little
structural and functional impairment.
In summary, for the ﬁrst time our study has shown experimentally
that the action of digitalis glycosides can positively or negatively in-
ﬂuence the survival during treatment of HF. It prolongs survival of
those in advanced states and compromises survival with cardiopa-
thies with little functional impairment. The results of this workemale rats according to Doppler echocardiogram predictors of mortality. Survival esti-
diameter; B) LVSD: left ventricle systolic diameter. *Pb0.05 (log rank test).
Table 3
Mortality rates for rats with myocardial infarctionb37% of left ventricle according to Doppler echocardiogram predictors of mortality.
Parameters Db37% Cb37% Δ R–R (CI) p
n Deaths n Deaths
LVDD≥0.82 cm 8 0 5 1 (20%) −20% 0.07 (0.00–4.17)
LVDDb0.82 cm 16 4 (25%) 22 0 25% 12.48 (1.68–92.68) 0.01
LVSD≥0.62 cm 6 0 11 1 (9%) −9% 0.21 (0.00–12.88)
LVSDb0.62 cm 18 4 (22%) 16 0 22% 7.20 (1.01–51.19) 0.049
LVDA≥0.42 cm² 6 2 (33%) 6 1 (17%) 16% 1.84 (0.19–17.71)
LVDAb0.42 cm² 18 2 (11%) 21 1 (5%) 6% 9.03 (0.56–146.1)
LVSA≥0.26 cm² 5 1 (20%) 7 1 (14%) 6% 1.30 (0.08–21.32)
LVSAb0.26 cm² 19 3 (16%) 20 0 16% 8.28 (0.86–79.86)
FAC≤37% 9 2 (22%) 4 1 (25%) −3% 0.75 (0.06–9.48)
FAC>37%% 15 2 (13%) 23 0 13% 13.30 (0.77–229.1)
E/A≥3.04 10 2 (20%) 4 0 20% 4.15 (0.20–86.28)
E/Ab3.04 13 1 (8%) 23 1 (4%) 4% 1.91 (0.11–34.87)
FAC≤37% e E/A≥3.04 6 1 (17%) 1 0 17% 3.21 (0.01–869.0)
FAC≤37% e E/A≥3.04 18 3 (17%) 25 1 (4%) 13% 4.09 (0.56–30.01)
D: digitoxin; C: control; R-R: relative risk; CI: 95% conﬁdence interval; LVDD: left ventricular diastolic diameter; LVSD: left ventricular systolic diameter; LVDA: left ventricular di-
astolic area; LVSA: left ventricular systolic area; FAC: fraction area change; E: E wave; A: A wave. * Values are absolute and relative frequencies. pb0,05 for comparison of the qual-
itative parameters (chi-square test) between control and digitoxin groups with MIb37%.
361A.A. dos Santos et al. / International Journal of Cardiology 167 (2013) 357–361support the important role of digitalis glycosides in the treatment of
HF. The effect of digitalis in reducing mortality depends on the inten-
sity of the cardiopathy. The greater beneﬁts occur when it is used in
heightened ventricular dilatations and worse mechanical function.
9. Limitations
The choice of female rats may confer certain gender-related bias to
the results. From this perspective, it should be noted that a previous
highly-regarded publication [1], which demonstrated the capacity of
angiotensin converting enzyme inhibitors to prolong the survival of in-
farcted rats, was also based on infarcted females. Currently, in clinical
practice, it is routine to use angiotensin converting enzyme inhibitors
and beta blockers in the treatment of heart failure. The inﬂuence of dig-
italis in the treatment of heart failure in association with angiotensin
converting enzyme inhibitors and beta blockers needs to be analyzed
and this is in progress in our lab. A more expressive sample of animals
withMIb37%would be desirable in order to bemore certain of the pos-
sible conclusions from the data. However, this limitation does not affect
the conclusion that digitoxin increases the survival of animals with
MI≥37%.
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